Bharat Biotech completes clinical development for phase III trials and booster doses for BBV154 intranasal covid vaccine.

In a separate development, BBIL, also announced that BBV154 (intra nasal vaccine) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries. 

BBV154 was developed in partnership with Washington University St Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, were conducted by Bharat Biotech. The Government of India partly funded product development and clinical trials through the Department of Biotechnology’s, COVID Suraksha program.


• Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2- dose) schedule; and a heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered covid vaccines in India. 

• Data from both Phase III human clinical trials have been submitted for approval to National Regulatory Authorities. 

• Primary dose schedule phase III trials were conducted for safety, and immunogenicity in ~3100 subjects, and compared with COVAXIN®. The trials were conducted in 14 trial sites across India. 

• Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects, where a booster dose (3rd dose) of BBV154 intranasal vaccine was administered to study participants who were previously vaccinated with licensed COVID vaccines. The trials were conducted in 9 trial sites across India.

• Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission. Further studies are being planned. 

• At the start of the COVID pandemic, Bharat Biotech commenced work on 4 platform technologies, the vero cell inactivated platform, and the adenoviral vector platform have been developed.

BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.

Recommended News